Affordable Access

Clinical pharmacokinetics and metabolism of bevantolol.

Authors
  • Latts, J R
Type
Published Article
Journal
Angiology
Publication Date
Mar 01, 1986
Volume
37
Issue
3 Pt 2
Pages
221–225
Identifiers
PMID: 2871781
Source
Medline
License
Unknown

Abstract

Bevantolol (the hydrochloride salt) has pharmacokinetic properties that are clinically advantageous. Bevantolol is well absorbed orally (greater than 70%); and the systemic bioavailability is 60%. Peak plasma concentrations are achieved 1 to 2 hours following an oral dose. Elimination is first-order with an average elimination half-life of 1.5 hours. Bevantolol exhibits linear pharmacokinetics within the therapeutic range (100 to 400 mg) with no change in half-life with chronic dosing. These properties result in predictable plasma levels and predictable drug response.

Report this publication

Statistics

Seen <100 times